Journal
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 36, Issue -, Pages 10-13Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfaa380
Keywords
albuminuria; chronic kidney disease; Dickkopf 3; precision medicine; progression
Categories
Funding
- Amicus Therapeutics UK Limited
- Boehringer Ingelheim RCV GmbH Co KG
- Astellas Pharma
- Vifor Pharma Osterreich GmbH
- European Union [848011]
Ask authors/readers for more resources
Progressive chronic kidney disease in individuals with type 2 diabetes mellitus is a global public health issue with challenges in predicting the individual course of the disease progression. Patterns of progression in CKD patients include both linear and nonlinear trajectories of GFR loss, with kidney function potentially remaining stable for years in the elderly.
Progressive chronic kidney disease (CKD) in individuals with type 2 diabetes mellitus is a global public health problem accompanied by substantial comorbidities and reduced life expectancy. In this respect, CKD leading to uremia can be seen as a systemic disease with a critical impact on virtually all organ systems. Thus it is of particular importance to identify patients with incipient CKD and ongoing CKD progression, but the individual course of CKD is challenging to predict. Patterns of progression in persons with CKD include linear and nonlinear trajectories of glomerular filtration rate (GFR) loss. Kidney function can also remain stable for years, especially in the elderly. In particular, one-fifth of individuals show a substantial GFR decline in the absence of high albuminuria (nonproteinuric CKD), rendering albuminuria less suitable for predicting the progression in such individuals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available